Spravato's list price is around $590–$885 per treatment session before insurance. With commercial coverage and Janssen's withMe copay-support program, eligible patients often pay $10 or less per session; Medicare Part B typically covers Spravato after prior authorization.
Spravato costs approximately $10 per session with commercial insurance plus the Janssen withMe copay program. Without insurance, list price is $590–$885 per session depending on dose.1
The clinic administration fee — the visit, monitoring, and REMS-network compliance — is billed separately and usually covered by insurance under standard medical benefits.
Medicare Part B patients pay the 20% Part B coinsurance unless they carry a supplement plan. Federal-plan patients cannot use the withMe copay program.
Spravato's wholesale acquisition cost (WAC) is set by Janssen at approximately $590 for a 56 mg session and $885 for an 84 mg session.1 Clinics buy the drug at or near WAC and bill your plan on top of that.
The list price is not what most patients pay. Insurance negotiation and copay assistance reduce the out-of-pocket sharply for eligible patients.
Spravato is only dispensed under a Risk Evaluation and Mitigation Strategy (REMS) program.4 That means it must be administered at a certified clinic under two-hour supervision.
Two things get billed at each visit: the drug (billed under HCPCS codes G2082 or G2083 depending on dose) and the clinic visit (billed as an evaluation and monitoring service).
Some clinics can "buy and bill" the drug directly; others use a specialty pharmacy that ships it to the clinic. The billing path affects your explanation of benefits but not your final cost.
The Janssen withMe program caps eligible commercial-insured patients at $10 per Spravato session for up to 12 months.2 The program pays the difference between your plan copay and $10.
Eligibility rules as of 2026:
Ask your clinic to help you enroll on your first authorization visit. Enrollment often takes less than 15 minutes.
Medicare Part B covers Spravato as a physician-administered drug under HCPCS G2082/G2083.3 Prior authorization applies in most Medicare Advantage plans.
Traditional Medicare beneficiaries typically owe the 20% Part B coinsurance. A Medigap or Medicare Advantage plan can reduce or eliminate that share. Medicare patients are not eligible for the withMe copay program.
Prior authorization for Spravato is required by nearly every commercial plan. Complete documentation shortens approval time.
See our insurance coverage guide for the appeal path if the plan denies the first submission.
The Spravato induction schedule is twice-weekly for four weeks, then weekly for four weeks, then every one to two weeks for maintenance. Total session count for the first six months is typically 16–24.
Session-count math (at approximate $10 with withMe, or $590–$885 list per session):
Uninsured patients pay list price — $590–$885 per session — unless they qualify for Janssen's patient assistance program. The assistance program is means-tested and provides free Spravato to eligible patients below a household income threshold.
Some REMS-certified clinics offer cash-pay bundles that combine the drug and administration for a fixed per-session price. Ask before booking.
After 12 months on withMe, copay support ends and the plan's standard cost-share resumes. Some patients transition to less frequent maintenance dosing to control cost.
If Spravato remains clinically indicated and the plan continues coverage, expect a per-session copay in the $30–$150 range on typical commercial plans. Some clinics can help patients apply to Janssen's patient assistance program for hardship coverage.
Three costs commonly surprise Spravato patients: the two-hour clinic supervision fee, transportation on dosing days, and lost work time.
Two-hour in-clinic monitoring is required by REMS. Some clinics bundle this into a single visit code; others bill it separately as an evaluation and management service. You cannot drive for 24 hours after dosing, so plan for a ride or transit both ways.
Twice-weekly induction dosing means eight half-days out of work in the first month. Factor that into your plan with your employer.
Get ketamine research & policy updates
New trials, FDA decisions, and legal changes for ketamine — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.